Ne Tarrant Internal Medicine Assoc, Llp

CLIA Laboratory Citation Details

2
Total Citations
16
Total Deficiencyies
14
Unique D-Tags
CMS Certification Number 45D0485154
Address 469 Westpark Way, Euless, TX, 76040
City Euless
State TX
Zip Code76040
Phone(817) 283-2888

Citation History (2 surveys)

Survey - April 21, 2022

Survey Type: Standard

Survey Event ID: OMLW11

Deficiency Tags: D0000 D5211 D5300 D5311 D5413 D5429 D5783 D6000 D6007 D2009

Summary:

Summary Statement of Deficiencies D0000 An entrance conference was held with the laboratory representatives. The survey process was discussed, and survey forms were provided. An opportunity for questions and comments was given. Noted deficiencies and plans of correction were discussed with the laboratory representatives at the exit conference. The laboratory representatives were given an opportunity to provide evidence of compliance with the noted deficiencies, and no such evidence was provided prior to survey exit. The facility was found to be NOT in compliance with the CLIA conditions for specialties /subspecialties surveyed for 42 CFR 493.1240 Pre-Analytic Systems 493.1403 Laboratory Director, (moderate complexity). Note: The CMS-2567 (Statement of Deficiencies) is an official, legal document. All information must remain unchanged except for entering the

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - October 6, 2021

Survey Type: Special

Survey Event ID: F7I111

Deficiency Tags: D0000 D2016 D2121 D2130 D6000 D6016

Summary:

Summary Statement of Deficiencies D0000 The following deficiencies are the result of a desk review of proficiency testing scores obtained from the CMS (Centers for Medicare and Medicaid) national database and verified with the proficiency testing company, American Proficiency Institute (API). The facility was found to be out of compliance with the conditions of participation of the CLIA program. The following CONDITION LEVEL DEFICIENCIES were found to be out of compliance: 493.803 Successful Participation 493.1403 Laboratory Director, (moderate complexity) D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing records, it was determined the Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- laboratory had not successfully participated in a proficiency testing program approved by HHS, for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. The laboratory did not successfully participate in the specialty of hematology for the analyte WBC Diff (White Blood Cell Differential). Refer to D2130. D2121 HEMATOLOGY CFR(s): 493.851(a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on a proficiency testing desk review of CMS form 155 and American Proficiency Institute (API) records, the laboratory failed to attain a score of at least 80% acceptable responses for each analyte in the specialty of hematology. Findings included: 1. Review of the CMS 0155 report revealed the following results: API 2020 - 3rd Event laboratory received an unsatisfactory score of 73% for WBC Diff. API 2021 - 2nd Event laboratory received an unsatisfactory score of 73 % for WBC Diff 2. Review of the laboratory's API proficiency testing records revealed the following results: API 2020 - 3rd Event laboratory received an unsatisfactory score of 73% for WBC Diff. API 2021 - 2nd Event laboratory received an unsatisfactory score of 73 % for WBC Diff Word Key: WBC Diff=White blood cell differential WBC=White blood cell D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a desk review of CMS 0155 form and American Proficiency Institute (API) proficiency testing records, it was determined the laboratory failed to achieve satisfactory performance (80% or better) for the same analyte in the specialty of hematology in two consecutive testing events or two out of three consecutive testing events. Two out of three unsatisfactory scores result in unsuccessful PT performance. Findings included: 1. Review of the CMS 0155 report revealed the following results: API 2020 - 3rd Event laboratory received an unsatisfactory score of 73% for WBC Diff. API 2021 - 2nd Event laboratory received an unsatisfactory score of 73 % for WBC Diff 2. Review of the laboratory's API proficiency testing records revealed the following results: API 2020 - 3rd Event laboratory received an unsatisfactory score of 73% for WBC Diff. API 2021 - 2nd Event laboratory received an unsatisfactory score of 73 % for WBC Diff D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. -- 2 of 3 -- This CONDITION is not met as evidenced by: Based on a desk review of laboratory proficiency testing performance it was revealed that the laboratory director failed to provide overall management and direction of the laboratory services. Refer to D6016 D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a desk review of proficiency testing results it was revealed that the laboratory director failed to ensure the overall quality of the laboratory services provided. The laboratory director failed to ensure successful participation in a HHS approved proficiency testing program. Refer to D2130 -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access